Claims for Patent: 9,421,184

Summary for Patent: 9,421,184

Title:	Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
Abstract:	The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof to a patient in need of such a treatment.
Inventor(s):	Saccone Valentina, Consalvi Silvia, Puri Pier Lorenzo, Mascagni Paolo
Assignee:	ITALFARMACO S.P.A.
Application Number:	US14444959
Patent Claims:	2. The method according to claim 1 , wherein said muscular dystrophy is Duchenne muscular dystrophy.3. The method according to claim 1 , wherein the administration to the patient is on a daily basis.4. The method according to claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride claim 1 , or the pharmaceutically acceptable salts and/or solvates thereof is administered in an amount ranging from 0.5 to 15 mg/kg/day.5. The method according to claim 1 , wherein said patient is a child.6. The method according to claim 5 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride claim 5 , or the pharmaceutically acceptable salts and/or solvates thereof is administered in an amount ranging from 1 to 10 mg/kg/day.7. The method according to claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride claim 1 , or the pharmaceutically acceptable salts and/or solvates thereof is administered in the form of a pharmaceutical composition comprising the same together with at least one physiologically acceptable excipient.8. The method according to claim 7 , wherein said pharmaceutical composition is administered by oral claim 7 , sublingual claim 7 , rectal claim 7 , intravascular claim 7 , intravenous claim 7 , or subcutaneous route.9. The method according to claim 7 , wherein said pharmaceutical composition is in a solid or a liquid form.10. The method according to claim 9 , wherein said solid form is selected from the group consisting of powder claim 9 , tablet claim 9 , granulate claim 9 , aggregate claim 9 , compressed pill claim 9 , coated pill claim 9 , hard gelatin capsule claim 9 , and gelatin capsule.11. The method according to claim 9 , wherein said liquid form is a suspension or a syrup.12. The method according to claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride is in a monohydrate form.13. The method according to claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride is in a crystal form.